atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million.
The merger is contingent upon the achievement of pre-agreed success criteria in Beckley’s ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.
Liberty Star Uranium & Metals Corp. (OTCQB:LBSR) (dba Liberty Star Minerals) said it has completed its registration with the System for Award Management (SAM), the federal government’s centralized platform for eligibility in contracts and grants.
The move enables Liberty Star to compete for federal funding across multiple government agencies, the company told shareholders in a statement.
Bit Digital Inc (NASDAQ:BTBT) announced that its wholly-owned high performance computing subsidiary WhiteFiber has acquired a 96-acre industrial property in North Carolina.
The company intends to retrofit the nearly one million square foot facility into a flagship AI data center campus.
US Gold Corp (NASDAQ:USAU) is set to be added to the Russell 3000 and Russell 2000 indexes following the conclusion of FTSE Russell’s annual reconstitution later this month.
Membership in the broad-market Russell 3000 Index, which comprises the largest 3,000 US public companies by market capitalization, results in automatic inclusion in the Russell 2000 Index for small-cap firms.
Spanish Mountain Gold Ltd (TSX-V:SPA, OTC:SPAZF) said on Monday it has confirmed extensive near-surface gold mineralization at the Phoenix Target, part of its flagship Spanish Mountain Gold project in British Columbia.
The company said drilling results define a mineralized zone around 1,450 metres long, 450 metres wide and up to 320 metres deep and open in all directions.
Lancaster Resources Inc (CSE:LCR, OTCQB:LANRF) announced that it has received final approval from the Canadian Securities Exchange for the acquisition of the Lake Cargelligo gold project, located in New South Wales, Australia.
With all key conditions satisfied, Lancaster said it expects the acquisition to close shortly.
Replenish Nutrients Holding Corp (CSE:ERTH, OTC:VVIVF) said it expects improving revenues, margins and cash flows in the coming quarters as its Beiseker granulation facility nears full commissioning and demand for its regenerative fertilizer products continues to climb.
The Canadian agricultural technology company, which reported a smaller net loss and improved cash flow from operating activities in the first quarter, said it anticipates reaching full production capacity at the Beiseker site by mid-year, ramping up to approximately 2,000 metric tonnes per month.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) shares rose 7% in afternoon trading after the company received US regulatory approval to expand the use of its lung imaging agent, XENOVIEW, to children as young as six.
The decision by the Food and Drug Administration lowers the age threshold from 12, potentially opening access to around one million additional patients.
Empire Metals Ltd (AIM:EEE, OTCQB:EPMLF) has kicked off a major new drilling campaign at its Pitfield Project in Western Australia.
With the new round of drilling, Empire aims to deliver a maiden JORC-compliant Mineral Resource Estimate at the Thomas Prospect.
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) has announced a retail offer of shares in the UK, alongside its new Australian IPO.
UK-based investors can subscribe for shares via RetailBook, with a minimum subscription of £250.
Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) said its lead cannabidiol medicine, MRX1, has passed a key regulatory milestone after achieving two years of stability data under internationally recognised pharmaceutical standards.
The UK-based company, which is developing approved CBD treatments for long-term health conditions, said the results meet guidelines set out by the International Council for Harmonisation.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has received approval from US regulators to expand the use of its lung imaging agent, XENOVIEW, to include children as young as six, opening access to an estimated one million additional patients.
The decision by the Food and Drug Administration lowers the minimum approved age from 12 to six years, allowing clinicians to use XENOVIEW with magnetic resonance imaging (MRI) to assess how well air moves through the lungs in younger patients.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) will present at the Gold Coast Investment Showcase on June 25–26, 2025 and hold an investor briefing in Brisbane on June 27. Chief executive officer Dr Daniel Tillett and executive chairman Dr Pete Smith will deliver company updates and engage directly with shareholders and prospective investors. These engagements come as the company continues clinical development of its lead asset, bisantrene (RC220), and pursues partnerships to broaden patient access.
Race will participate in the upcoming Gold Coast Investment Showcase held at the JW Marriott Gold Coast Resort & Spa, with Tillett scheduled to present at 10:30 am on Thursday, June 26. He will also be available across both days at the Race booth to meet with attendees and discuss the company’s latest developments, including progress on its RC220 formulation and clinical programs.
Last week, Cobalt Blue Holdings Ltd (ASX:COB, OTC:CBBHF) announced a major supply agreement with Glencore International to support its Kwinana cobalt refinery. CEO Dr Andrew Tong said the deal covers up to 50% of its cobalt hydroxide requirements over an initial three-year term.
